Advertisement

News From the 2022 ASCO Genitourinary Cancers Symposium


The 2022 ASCO Genitourinary Cancers Symposium kicked off this week. On this episode, we’ll hear about two studies presented at the meeting: one, focused on a genetic risk score that may aid in identifying men with high vs low lifetime risks of developing metastatic prostate cancer or dying from prostate cancer; and the second, about a trial that tested the efficacy of combination immunotherapy and tyrosine kinase inhibitor therapy for renal cell carcinoma.




Advertisement
Advertisement

Advertisement




Advertisement